We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : MLSC Blood decontaminant recieves patent!!!

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cindy Powell who wrote (192)1/17/2001 1:04:57 PM
From: Cindy Powell  Read Replies (1) of 196
Medical Discoveries, Inc. Receives Eighth Patent
SALT LAKE CITY, Jan. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has received Patent Number 6,117,285 from the United States Patent And Trademark Office, entitled ``System For Carrying Out Sterilization Of Equipment.''

Medical Discoveries, Inc. (MDI) now has a total of eight granted patents relating to the company's proprietary electrolysis devices, methods and the patented products and applications derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, begun in 1992 with proprietary hydrolysis of saline solutions for microbicidal applications and the development of a patented machine to produce these products.

MDI's patents and resulting intellectual properties now span more than a decade of research and development, and include:

Patent No. Patent No. Patent No. Patent No.
5,334,383 5,507,932 5,560,816 5,622,848
"Electrically "Apparatus For "Method For "Electrically
Hydrolyzed Electrolyzing Electrolyzing Hydrolyzed Saline
Salines As Fluids" Fluids" Solutions As
In Vivo [1996] [1996] Microbicides
Microbicides For In Vitro
For Treatment Of Treatment Of
Cardiomyopathy Contaminated
And Multiple Fluids Containing
Sclerosis." Blood"
[1994] [1997]

Patent No. Patent No. Patent No. Patent No.
5,674,537 5,731,008 6,007,686 6,117,285
"An Electrolyzed "Electrically "System For "System For
Saline Solution Hydrolyzed Electrolyzing Carrying Out
Containing Salines As Fluids For Use Sterilization
Concentrated Microbicides" As Antimicrobial Of Equipment"
Amounts Of Ozone [1998] Agents" [2000]
And Chlorine [1999]

The Company has foreign PCT patent applications pending, corresponding to the above-granted United States patents.

Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P.

MDI-P is a solution-based drug, which is produced by the electrolysis of saline, using a patented instrument with proprietary electrodes. This solution has a significant oxidation reduction potential due to a mixture of oxidative products resulting from electrolysis.

Medical Discoveries, Inc. has identified several major target markets for its innovative new drug MDI-P. Each contains opportunities for MDI-P to play a major role in existing and new treatments of major diseases, as well as sterilization and disinfectant applications that represent major advances over current technologies. Medical Discoveries, Inc. intends to move forward in these areas of continued testing and development in the near term, while continuing to research and investigate additional applications for the Company's proprietary technology. MDI intends to vigorously pursue additional patents for its applications while safeguarding the Company's current intellectual properties.

Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies.

Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.

SOURCE: Medical Discoveries, Inc.
Wednesday January 10, 10:40 am Eastern Time
Press Release
SOURCE: Medical Discoveries, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext